[go: up one dir, main page]

WO2020023530A3 - Methods of treatment and prevention of alzheimer's disease - Google Patents

Methods of treatment and prevention of alzheimer's disease Download PDF

Info

Publication number
WO2020023530A3
WO2020023530A3 PCT/US2019/043067 US2019043067W WO2020023530A3 WO 2020023530 A3 WO2020023530 A3 WO 2020023530A3 US 2019043067 W US2019043067 W US 2019043067W WO 2020023530 A3 WO2020023530 A3 WO 2020023530A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
disease
alzheimer
subject
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/043067
Other languages
French (fr)
Other versions
WO2020023530A2 (en
Inventor
Johan Luthman
Chad J. SWANSON
Yong Zhang
Shobha DHADDA
Jinping Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201980062781.8A priority Critical patent/CN112805031A/en
Priority to MX2021000778A priority patent/MX2021000778A/en
Priority to BR112021001272-9A priority patent/BR112021001272A2/en
Priority to JP2021503770A priority patent/JP7541505B2/en
Priority to IL280315A priority patent/IL280315B2/en
Priority to AU2019309938A priority patent/AU2019309938A1/en
Priority to KR1020217005322A priority patent/KR20210039402A/en
Priority to US17/250,448 priority patent/US20210324056A1/en
Priority to CN202411217698.2A priority patent/CN118924896A/en
Priority to CA3107370A priority patent/CA3107370A1/en
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Priority to EP19750196.8A priority patent/EP3826674A2/en
Publication of WO2020023530A2 publication Critical patent/WO2020023530A2/en
Publication of WO2020023530A3 publication Critical patent/WO2020023530A3/en
Priority to PH12021500006A priority patent/PH12021500006A1/en
Anticipated expiration legal-status Critical
Priority to IL310132A priority patent/IL310132B1/en
Priority to JP2024077300A priority patent/JP2024112859A/en
Priority to IL323583A priority patent/IL323583A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided herein are methods of reducing clinical decline in a subject having early Alzheimer's disease, methods of converting an amyloid positive subject having early Alzheimer's disease to amyloid negative, methods of reducing brain amyloid level in a subject, and methods of preventing Alzheimer's disease, the methods comprising administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. In some embodiments, the subject is ApoE4-positive. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
PCT/US2019/043067 2018-07-24 2019-07-23 Methods of treatment and prevention of alzheimer's disease Ceased WO2020023530A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
MX2021000778A MX2021000778A (en) 2018-07-24 2019-07-23 METHODS OF TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE.
BR112021001272-9A BR112021001272A2 (en) 2018-07-24 2019-07-23 methods of treatment and prevention of alzheimer's disease
JP2021503770A JP7541505B2 (en) 2018-07-24 2019-07-23 Methods for Treating and Preventing Alzheimer's Disease
IL280315A IL280315B2 (en) 2018-07-24 2019-07-23 Methods of treatment and prevention of alzheimer's disease
AU2019309938A AU2019309938A1 (en) 2018-07-24 2019-07-23 Methods of treatment and prevention of alzheimer's disease
KR1020217005322A KR20210039402A (en) 2018-07-24 2019-07-23 Alzheimer's disease treatment and prevention methods
US17/250,448 US20210324056A1 (en) 2018-07-24 2019-07-23 Methods of treatment and prevention of alzheimer's disease
CA3107370A CA3107370A1 (en) 2018-07-24 2019-07-23 Methods of treatment and prevention of alzheimer's disease
CN202411217698.2A CN118924896A (en) 2018-07-24 2019-07-23 Method for treating and preventing Alzheimer's disease
CN201980062781.8A CN112805031A (en) 2018-07-24 2019-07-23 Methods for treating and preventing alzheimer's disease
EP19750196.8A EP3826674A2 (en) 2018-07-24 2019-07-23 Methods of treatment and prevention of alzheimer's disease
PH12021500006A PH12021500006A1 (en) 2018-07-24 2021-01-21 Methods of treatment and prevention of alzheimer's disease
IL310132A IL310132B1 (en) 2018-07-24 2024-01-14 Methods of treatment and prevention of alzheimer's disease
JP2024077300A JP2024112859A (en) 2018-07-24 2024-05-10 Methods for Treating and Preventing Alzheimer's Disease
IL323583A IL323583A (en) 2018-07-24 2025-09-25 Methods of treatment and prevention of alzheimer's disease

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201862702659P 2018-07-24 2018-07-24
US62/702,659 2018-07-24
US201862749614P 2018-10-23 2018-10-23
US62/749,614 2018-10-23
US201962824162P 2019-03-26 2019-03-26
US62/824,162 2019-03-26
US201962846902P 2019-05-13 2019-05-13
US62/846,902 2019-05-13
US201962874684P 2019-07-16 2019-07-16
US62/874,684 2019-07-16

Publications (2)

Publication Number Publication Date
WO2020023530A2 WO2020023530A2 (en) 2020-01-30
WO2020023530A3 true WO2020023530A3 (en) 2020-03-12

Family

ID=67551415

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/043067 Ceased WO2020023530A2 (en) 2018-07-24 2019-07-23 Methods of treatment and prevention of alzheimer's disease

Country Status (13)

Country Link
US (1) US20210324056A1 (en)
EP (1) EP3826674A2 (en)
JP (2) JP7541505B2 (en)
KR (1) KR20210039402A (en)
CN (2) CN112805031A (en)
AU (1) AU2019309938A1 (en)
BR (1) BR112021001272A2 (en)
CA (1) CA3107370A1 (en)
IL (3) IL280315B2 (en)
MX (1) MX2021000778A (en)
PH (1) PH12021500006A1 (en)
TW (1) TW202019471A (en)
WO (1) WO2020023530A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7368856B2 (en) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Cancer treatment by blocking the interaction between TIM-3 and its ligand
PH12022552172A1 (en) * 2020-03-20 2023-12-11 Eisai R&D Man Co Ltd High concentration anti-a㟠protofibril antibody formulations and methods of use thereof
CA3185040A1 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
TW202216760A (en) 2020-07-23 2022-05-01 愛爾蘭商歐薩爾普羅席納有限公司 Anti-abeta antibodies
WO2022035758A1 (en) * 2020-08-12 2022-02-17 The Cleveland Clinic Foundation Bace1 inhibitor treatment for suppressing cytokine storm
TW202300517A (en) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 Anti-amyloid beta antibodies and uses thereof
WO2023111618A1 (en) * 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
US20250051427A1 (en) * 2021-12-17 2025-02-13 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
EP4473009A1 (en) * 2022-02-02 2024-12-11 Eisai R&D Management Co., Ltd. Methods of treatment using p-tau181 level

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016087944A2 (en) * 2014-12-02 2016-06-09 Biogen International Neuroscience Gmbh Method for treating alzheimer's disease
AU2016208353B2 (en) * 2007-10-17 2017-07-20 Janssen Alzheimer Immunotherapy Immunotherapy regimes dependent on ApoE status
WO2017127764A1 (en) * 2016-01-20 2017-07-27 Genentech, Inc. High dose treatments for alzheimer's disease
WO2017194789A1 (en) * 2016-05-13 2017-11-16 Institut Pasteur Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
WO2018005282A1 (en) * 2016-07-01 2018-01-04 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
WO2018081460A1 (en) * 2016-10-27 2018-05-03 Eisai R&D Management Co., Ltd. Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2082749A3 (en) 2000-07-07 2010-06-30 Bioarctic Neuroscience AB Prevention and treatment of Alzheimer's disease
SE0401601D0 (en) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
PL2004688T5 (en) 2006-03-23 2014-09-30 Bioarctic Neuroscience Ab Improved antibodies to protofibrils and their uses
JO3076B1 (en) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
PT2233474E (en) 2008-01-18 2015-10-26 Eisai R&D Man Co Ltd Condensed aminodihydrothiazine derivative
PT2448968T (en) 2009-06-29 2021-04-30 Bioarctic Ab N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer`s disease
WO2011106732A1 (en) * 2010-02-25 2011-09-01 Wyeth Llc Pet monitoring of ab-directed immunotherapy
DK2539366T3 (en) 2010-02-26 2018-02-05 Bioarctic Neuroscience Ab PROTOFIBRIL-BINDING ANTIBODIES AND THEIR USE IN THERAPEUTIC AND DIAGNOSTIC PROCEDURES FOR PARKINSON'S DISEASE, DEMENS WITH LEWY BODY AND OTHER ALPHA SYNUCLEINOPATHIES
BR112013016241A2 (en) 2011-01-21 2016-07-12 Eisai R&D Man Co Ltd compound, and method for making a compound
UA121550C2 (en) * 2014-07-10 2020-06-25 ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016208353B2 (en) * 2007-10-17 2017-07-20 Janssen Alzheimer Immunotherapy Immunotherapy regimes dependent on ApoE status
WO2016087944A2 (en) * 2014-12-02 2016-06-09 Biogen International Neuroscience Gmbh Method for treating alzheimer's disease
WO2017127764A1 (en) * 2016-01-20 2017-07-27 Genentech, Inc. High dose treatments for alzheimer's disease
WO2017194789A1 (en) * 2016-05-13 2017-11-16 Institut Pasteur Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
WO2018005282A1 (en) * 2016-07-01 2018-01-04 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
WO2018081460A1 (en) * 2016-10-27 2018-05-03 Eisai R&D Management Co., Ltd. Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VERONIKA LOGOVINSKY ET AL: "Safety and tolerability of BAN2401 - a clinical study in Alzheimer's disease with a protofibril selective A[beta] antibody", ALZHEIMER'S RESEARCH & THERAPY, vol. 8, no. 1, 6 April 2016 (2016-04-06), XP055655198, DOI: 10.1186/s13195-016-0181-2 *

Also Published As

Publication number Publication date
IL323583A (en) 2025-11-01
JP2024112859A (en) 2024-08-21
IL310132A (en) 2024-03-01
WO2020023530A2 (en) 2020-01-30
JP7541505B2 (en) 2024-08-28
JP2021532126A (en) 2021-11-25
IL310132B1 (en) 2025-11-01
EP3826674A2 (en) 2021-06-02
IL280315B1 (en) 2024-02-01
MX2021000778A (en) 2021-03-31
TW202019471A (en) 2020-06-01
KR20210039402A (en) 2021-04-09
CN112805031A (en) 2021-05-14
AU2019309938A1 (en) 2021-03-11
IL280315A (en) 2021-03-25
CA3107370A1 (en) 2020-01-30
IL280315B2 (en) 2024-06-01
BR112021001272A2 (en) 2021-04-27
CN118924896A (en) 2024-11-12
US20210324056A1 (en) 2021-10-21
PH12021500006A1 (en) 2021-09-13

Similar Documents

Publication Publication Date Title
WO2020023530A3 (en) Methods of treatment and prevention of alzheimer's disease
EP4491229A3 (en) Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
PH12020500555A1 (en) Esketamine for the treatment of depression
MA47313B1 (en) Her2 antibody subcutaneous formulations
AU2017291414B2 (en) Anti-N3pGLu amyloid beta peptide antibodies and uses thereof
EP3708168A3 (en) Combinations of deuterated dextromethorphan and quinidine for the treatment of agitation in dementia
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
MX2023005628A (en) Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease.
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
MX2024007642A (en) Use of riluzole oral disintigrating tablets for treating diseases.
MX2024002567A (en) Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof.
WO2021023069A8 (en) Application of tpk as a target in alzheimer's disease
WO2021038500A3 (en) Esketamine for the treatment of patients with major depressive disorder, including suicidality
MX2021009488A (en) USE OF VIBEGRON TO TREAT OVERACTIVE BLADDER.
EA202193190A1 (en) COMPOSITION INCLUDING PRIDOPIDINE AND ITS ANALOGUE FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND ITS SYMPTOMS
WO2020170030A3 (en) Method for providing early onset of action in the treatment of rosacea
NZ812760A (en) Methods of treatment and prevention of alzheimer’s disease
EP4523750A3 (en) Methods of reducing cerebrovascular events in patients with fabry disease
EP4327815A3 (en) Probiotics for regulating blood glucose
MX2021008986A (en) Methods of treating a patient having parkinson's disease.
WO2023049534A3 (en) Subcutaneously administered foslevodopa/foscarbidopa treatments for advanced parkinson's disease
WO2022192639A3 (en) Anti-n3pglu amyloid beta antibodies and uses thereof
MY203365A (en) Montelukast for the treatment of erosive hand osteoarthritis
BRPI0511305A (en) method of relieving an annular or sarcoid granuloma, manufactured article and use of an lfa-1 antagonist
WO2005041870A3 (en) Composition and method for the treatment of eye disease

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3107370

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021503770

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021001272

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20217005322

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019750196

Country of ref document: EP

Effective date: 20210224

ENP Entry into the national phase

Ref document number: 2019309938

Country of ref document: AU

Date of ref document: 20190723

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19750196

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112021001272

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210122

WWR Wipo information: refused in national office

Ref document number: 1020217005322

Country of ref document: KR

WWD Wipo information: divisional of initial pct application

Ref document number: 323583

Country of ref document: IL